

Azmil H Abdul-Rahim

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3026543/azmil-h-abdul-rahim-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140
papers

30,587
citations

47
h-index

142
g-index

142
ext. papers

36,713
ext. citations

11.2
avg, IF

6.89
L-index

#	Paper	IF	Citations
140	Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study.. <i>Stroke</i> , 2022 , STROKEAHA121036695	6.7	2
139	Paired vagus nerve stimulation for treatment of upper extremity impairment after stroke.. <i>International Journal of Stroke</i> , 2022 , 17474930221094684	6.3	0
138	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study.. <i>Stroke</i> , 2022 , 101161STROKEAHA121038239	6.7	1
137	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021 , 143, 516-525	16.7	85
136	Ultrasound imaging of congestion in heart failure: examinations beyond the heart. <i>European Journal of Heart Failure</i> , 2021 , 23, 703-712	12.3	21
135	Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1147-1155	12.3	4
134	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2021 , 52, 1450-1454	6.7	2
133	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 386-397	7.9	2
132	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 1875-1887	12.3	14
131	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021 , 44, 1894-1897	14.6	11
130	Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. <i>Diabetes Care</i> , 2021 , 44, 1877-1884	14.6	7
129	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1477-1484	12.3	1
128	Effect of Nephilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021 , 144, 199-209	16.7	14
127	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021 , 143, 438-448	16.7	36
126	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. <i>ESC Heart Failure</i> , 2021 , 8, 129-138	3.7	6
125	Urate, Blood Pressure, and Cardiovascular Disease: Evidence From Mendelian Randomization and Meta-Analysis of Clinical Trials. <i>Hypertension</i> , 2021 , 77, 383-392	8.5	15
124	Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. <i>The Cochrane Library</i> , 2021 , 2, CD013306	5.2	14

123	Sex differences in congestive markers in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 1784-1795	3.7	2
122	Biomarkers for Atrial Fibrillation Detection After Stroke: Systematic Review and Meta-analysis. <i>Neurology</i> , 2021 , 97, e1775-e1789	6.5	5
121	Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". <i>Circulation</i> , 2021 , 144, e40	16.7	2
120	The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1595-1604	3.7	7
119	Cardiorenal risk reduction guidance in diabetes: can we reach consensus?. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 357-360	18.1	8
118	Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020 , 382, 1653-1659	59.2	1316
117	Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. <i>Stroke</i> , 2020 , 51, 2347-2354	6.7	5
116	Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1201-1209	3.7	10
115	The impact of atrial fibrillation type on the risks of thromboembolic recurrence, mortality and major haemorrhage in patients with previous stroke: A systematic review and meta-analysis of observational studies. <i>European Stroke Journal</i> , 2020 , 5, 155-168	5.6	3
114	Improving economic evaluations in stroke: A report from the ESO Health Economics Working Group. <i>European Stroke Journal</i> , 2020 , 5, 184-192	5.6	8
113	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 506-522	9.4	20
112	Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1311-1319	3.9	1
111	Early in-hospital exposure to statins and outcome after intracerebral haemorrhage - Results from the Virtual International Stroke Trials Archive. <i>European Stroke Journal</i> , 2020 , 5, 85-93	5.6	4
110	BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020 , 14, 1149-1151	8.9	49
109	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. <i>European Stroke Journal</i> , 2020 , 5, 374-383	5.6	1
108	The Incidence and Associated Factors of Early Neurological Deterioration After Thrombolysis: Results From SITS Registry. <i>Stroke</i> , 2020 , 51, 2705-2714	6.7	12
107	Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. <i>Circulation</i> , 2020 , 142, 4-6	16.7	375
106	Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes. <i>JACC: Heart Failure</i> , 2019 , 7, 849-858	7.9	65

105	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1199-1208	6.7	51
104	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 844-851	12.3	47
103	Anticoagulation After Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2019 , 50, 2093-2100	6.7	17
102	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2019 , 50, 2168-2174	6.7	31
101	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 1022-1031	12.3	14
100	Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. <i>European Journal of Heart Failure</i> , 2019 , 21, 699-702	12.3	5
99	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 337-341	12.3	69
98	Stroke aetiological classification reliability and effect on trial sample size: systematic review, meta-analysis and statistical modelling. <i>Trials</i> , 2019 , 20, 107	2.8	2
97	Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke. <i>European Stroke Journal</i> , 2019 , 4, 55-64	5.6	2
96	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. <i>Korean Circulation Journal</i> , 2019 , 49, 469-484	2.2	12
95	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , 2019 , 42, 1792-1799	14.6	25
94	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). <i>Journal of the American College of Cardiology</i> , 2019 , 74, 683-698	15.1	11
93	The role of single pill combination therapy in the prevention of ischaemic stroke. <i>Scottish Medical Journal</i> , 2019 , 64, 126-132	1.8	1
92	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018 , 137, 961-972	16.7	175
91	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 853-872	12.3	264
90	Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 1139-1145	12.3	26
89	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart Failure</i> , 2018 , 11, e011515	7.6	34
88	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative). <i>American Journal of Cardiology</i> , 2018 , 121, 1015-1020	3	10

87	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018 , 20, 1230-1239	12.3	159
86	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 727-735	15.1	18
85	Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018 , 47, 117-135	5.5	16
84	Professional guideline versus product label selection for treatment with IV thrombolysis: An analysis from SITS registry. <i>European Stroke Journal</i> , 2018 , 3, 39-46	5.6	5
83	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. <i>European Journal of Heart Failure</i> , 2018 , 20, 268-277	12.3	25
82	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 136-147	12.3	15
81	Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. <i>European Journal of Heart Failure</i> , 2018 , 20, 938-940	12.3	14
80	Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?. <i>European Journal of Heart Failure</i> , 2018 , 20, 317-322	12.3	14
79	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. <i>Clinical Epidemiology</i> , 2018 , 10, 917-930	5.9	4
78	A survey of opinion: When to start oral anticoagulants in patients with acute ischaemic stroke and atrial fibrillation?. <i>European Stroke Journal</i> , 2018 , 3, 355-360	5.6	10
77	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018 , 138, 1505-1514	16.7	79
76	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018 , 122, 1506-1512	3	11
75	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 504-510	12.3	37
74	Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. <i>Journal of the American Heart Association</i> , 2018 , 7, e010133	6	35
73	Are you suffering from a large arterial occlusion? Please raise your arm!. <i>Stroke and Vascular Neurology</i> , 2018 , 3, 215-221	9.1	4
72	Clinical Selection Strategies to Identify Ischemic Stroke Patients With Large Anterior Vessel Occlusion: Results From SITS-ISTR (Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Registry). <i>Stroke</i> , 2017 , 48, 290-297	6.7	84
71	Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	55
70	Prestroke CHADS-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017 , 26, 1363-1368	2.8	5

69	Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study. <i>Stroke</i> , 2017 , 48, 726-732	6.7	28
68	Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation). <i>European Stroke Journal</i> , 2017 , 2, 46-53	5.6	2
67	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 295-301	3.9	2
66	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017 , 188, 35-41	4.9	24
65	Sex and Stroke in Thrombolysed Patients and Controls. <i>Stroke</i> , 2017 , 48, 367-374	6.7	16
64	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	37
63	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017 , 38, 742-750	9.5	25
62	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	60
61	Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 673-681	12.3	28
60	Zinc containing dental fixative causing copper deficiency myelopathy. <i>BMJ Case Reports</i> , 2017 , 2017,	0.9	1
59	Return to the Workforce After First Hospitalization for Heart Failure: A Danish Nationwide Cohort Study. <i>Circulation</i> , 2016 , 134, 999-1009	16.7	29
58	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	53
57	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016 , 1, 93-100	5.6	
56	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	35
55	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	68
54	Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. <i>Journal of Neurology</i> , 2016 , 263, 231-237	5.5	27
53	Statins and risk of poststroke hemorrhagic complications. <i>Neurology</i> , 2016 , 86, 1590-6	6.5	20
52	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. <i>International Journal of Cardiology</i> , 2016 , 209, 310-6	3.2	19

51	Online Tool to Improve Stratification of Adverse Events in Stroke Clinical Trials. <i>Stroke</i> , 2016 , 47, 882-5	6.7	1
50	Derivation and Validation of a Novel Prognostic Scale (Modified-Stroke Subtype, Oxfordshire Community Stroke Project Classification, Age, and Prestroke Modified Rankin) to Predict Early Mortality in Acute Stroke. <i>Stroke</i> , 2016 , 47, 74-9	6.7	19
49	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016 , 37, 3167-3174	6.7	88
48	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1021-31	12.3	13
47	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). <i>Circulation</i> , 2016 , 133, 2254-62	16.7	96
46	Hearts and minds association, causation and implication of cognitive impairment in heart failure. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 22	9	53
45	Feasibility platform for stroke studies: an online tool to improve eligibility criteria for clinical trials. <i>Stroke</i> , 2015 , 46, 137-42	6.7	5
44	Screening for atrial fibrillation after stroke or TIA. <i>Lancet Neurology</i> , 2015 , 14, 345-7	24.1	4
43	Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. <i>Stroke</i> , 2015 , 46, 2175-82	6.7	157
42	Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. <i>European Journal of Heart Failure</i> , 2015 , 17, 196-204	12.3	12
41	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials. <i>Circulation</i> , 2015 , 131, 1486-94; discussion 1494	16.7	66
40	National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome: External Validation on Safe Implementation of Thrombolysis in Stroke-Monitoring Study Data. <i>Stroke</i> , 2015 , 46, 2779-85	6.7	14
39	Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials." <i>Circulation</i> , 2015 , 132, e358	16.7	1
38	National institutes of health stroke scale item profiles as predictor of patient outcome: external validation on independent trial data. <i>Stroke</i> , 2015 , 46, 395-400	6.7	24
37	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. <i>European Journal of Heart Failure</i> , 2015 , 17, 809-17	12.3	45
36	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. <i>European Journal of Heart Failure</i> , 2015 , 17, 1182-91	12.3	37
35	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation</i> , 2015 , 131, 54-61	16.7	430
34	Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation. <i>Heart</i> , 2014 , 100, 557-62	5.1	17

33	Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>New England Journal of Medicine</i> , 2014 , 371, 993-1004	59.2	3301
32	Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 590-5	7.6	97
31	Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014 , 7, 953-9	7.6	62
30	Depression and anxiety symptoms post-stroke/TIA: prevalence and associations in cross-sectional data from a regional stroke registry. <i>BMC Neurology</i> , 2014 , 14, 198	3.1	66
29	Characteristic adverse events and their incidence among patients participating in acute ischemic stroke trials. <i>Stroke</i> , 2014 , 45, 2677-82	6.7	12
28	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2013 , 62, e147-239	15.1	4318
27	Paroxysmal atrial fibrillation after ischemic stroke: how should we hunt for it?. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 485-94	2.5	8
26	Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. <i>Circulation: Heart Failure</i> , 2013 , 6, 203-10	7.6	24
25	Baseline characteristics of patients in the Reduction of Events with Darbeopetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , 2013 , 15, 334-41	12.3	20
24	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 1387-95	40	756
23	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2012 , 14, 803-69	12.3	1892
22	Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. <i>Circulation</i> , 2012 , 126, 2317-23	16.7	73
21	How small is too small? A systematic review of center volume and outcome after cardiac transplantation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 783-90	5.8	31
20	Eplerenone in patients with systolic heart failure and mild symptoms. <i>New England Journal of Medicine</i> , 2011 , 364, 11-21	59.2	1890
19	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856
18	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011 , 13, 755-64	12.3	15
17	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. <i>European Heart Journal</i> , 2011 , 32, 1227-34	9.5	114
16	Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. <i>Circulation</i> , 2010 , 122, 597-602	16.7	148

15	Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. <i>European Journal of Heart Failure</i> , 2010 , 12, 17-24	12.3	65
14	An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 66-74	12.3	15
13	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 607-16	12.3	50
12	Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial infarction trial (VALIANT). <i>European Heart Journal</i> , 2009 , 30, 1450-6	9.5	40
11	Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. <i>Circulation</i> , 2009 , 119, 515-23	16.7	393
10	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , 2009 , 11, 170-7	12.3	247
9	Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). <i>American Heart Journal</i> , 2009 , 157, 271-7	4.9	123
8	Diabetes, left ventricular systolic dysfunction, and chronic heart failure. <i>European Heart Journal</i> , 2008 , 29, 1224-40	9.5	152
7	Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008 , 10, 149-56	12.3	144
6	Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Alternative trial. <i>European Journal of Heart Failure</i> , 2008 , 10, 157-63	12.3	23
5	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008 , 29, 1377-85	9.5	419
4	Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. <i>Circulation</i> , 2007 , 116, 1482-7	16.7	400
3	Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>New England Journal of Medicine</i> , 2003 , 349, 1893-906	59.2	1892
2	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , 2003 , 362, 759-66	40	1506
1	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. <i>Lancet, The</i> , 2003 , 362, 772-6	40	1362